Compare ELME & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELME | PYXS |
|---|---|---|
| Founded | 1960 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.5M | 141.3M |
| IPO Year | 1994 | 2021 |
| Metric | ELME | PYXS |
|---|---|---|
| Price | $1.75 | $1.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | ★ 1.1M | 1.1M |
| Earning Date | 10-22-2026 | 11-02-2026 |
| Dividend Yield | ★ 838.29% | N/A |
| EPS Growth | N/A | ★ 3.03 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $206,360,000.00 | $13,858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $52.13 | $14,188.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.26 | $1.03 |
| 52 Week High | $17.68 | $5.55 |
| Indicator | ELME | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 61.70 | 28.37 |
| Support Level | $1.62 | $1.90 |
| Resistance Level | $2.06 | $2.17 |
| Average True Range (ATR) | 0.02 | 0.18 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 92.86 | 4.10 |
Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. It derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Elme Communities' tenants are banking, consulting, law, and financial services firms. The company operates in a single reportable segment which includes the ownership, development, redevelopment and acquisition of apartment communities.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.